Coronavirus CoverageIn this July 27, 2020, file photo, nurse Kathe Olmstead prepares a shot that is part of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., in Binghamton, N. Y. (Hans Pennink/AP File)Although approval is still not guaranteed, Moderna’s coronavirus vaccine has now cleared by a long shot the hurdles the Food and Drug Administration initially set for emergency use authorization. The agency requires vaccine makers to show at least two months of safety data with no serious negative reactions and at least a 50% efficacy rate. On Monday, Cambridge-based Moderna announced its phase three clinical trial shows the vaccine has a 94.1% efficacy rate and no significant safety concerns, after two months of study. Dr. Tal Zaks, the company’s chief medical officer, relayed the results to senior staff over a video call in the morning. The staff erupted into applause.“It’s hard to tell you how exuberant we were,” says Ray Jordan, Moderna’s head of corporate affairs. “Most everyone is on mute in a big meeting, and you just start seeing hands moving. Then people started unmuting. It was a big moment. It was just the feeling like, ‘This is making a difference. It may be saving lives.’ ”Zaks received the company’s latest report Sunday night, hours before the senior staff. Speaking to the Associated Press, he said he expected the vaccine to be highly effective at preventing COVID-19, the disease caused by the coronavirus, but he was still moved by the data.“When I saw the final results last night, I allowed myself to cry for the first time,” he says. Now, following Pfizer, Moderna has become the second company to file an emergency use application with the FDA for a coronavirus vaccine. An FDA advisory panel is expected to review the applications by mid-December, and Moderna’s Jordan says vaccine distribution may begin before the end of 2020.“This is a pivotal moment for the program. The work is really ramping up for a number of teams,” Jordan says. “Boy, the manufacturing team is in a spotlight now.”The biotech is prepared to deliver 20 million doses to the United States in December or early January, as well as another 100 million in 2021. Both Moderna and Pfizer also have contracts with other countries to deliver vaccine doses, and the U. S. government has the option to purchase more of the vaccines. From there, state and federal officials will determine priorities for vaccine distribution. Elders and frontline workers are expected to be highest on the list for receiving the vaccines, which both require two doses. The basis of the Moderna and Pfizer vaccines is modified mRNA, short for messenger RNA. This is a type of genetic code that instructs cells to build proteins. Moderna and other vaccine makers engineered a piece of mRNA that cells use to construct the spike on the outside of the coronavirus. The body’s immune system uses that viral fragment to build a defense against the virus.
All data is taken from the source:
Article Link:
#Moderna #newsusa #bbcnewsworld #newstodaymsnbc #newstodayworld #newsworldnow #
